» Articles » PMID: 8251051

Preliminary Findings of High-dose Thiamine in Dementia of Alzheimer's Type

Overview
Publisher Sage Publications
Date 1993 Oct 1
PMID 8251051
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Thiamine is important not only in the metabolism of acetylcholine but also in its release from the presynaptic neuron. Pathologic, clinical, and biochemical data suggest that thiamine deficiency is detrimental to the cholinergic system and that thiamine-dependent enzymes may be altered in Alzheimer's disease. Two previous studies reported contradictory results in patients with dementia of Alzheimer's type treated with 3 g/day of thiamine. In the present study, we examined the effects of 3 to 8 g/day thiamine administered orally. Our results suggest that thiamine at these pharmacologic dosages may have a mild beneficial effect in dementia of Alzheimer's type. The mechanism of the observed effect is unknown, but the findings warrant further investigation, not only for their therapeutic implications but for their possible etiologic clues. In addition, the results suggest long-term carry-over effects that should be considered in the design of future studies.

Citing Articles

Mitochondrial Dysfunction and Neurodegenerative Disorders: Role of Nutritional Supplementation.

Mantle D, Hargreaves I Int J Mol Sci. 2022; 23(20).

PMID: 36293457 PMC: 9604531. DOI: 10.3390/ijms232012603.


Pharmacological thiamine levels as a therapeutic approach in Alzheimer's disease.

Gibson G, Feldman H, Zhang S, Flowers S, Luchsinger J Front Med (Lausanne). 2022; 9:1033272.

PMID: 36275801 PMC: 9585656. DOI: 10.3389/fmed.2022.1033272.


Supplemental thiamine as a practical, potential way to prevent Alzheimer's disease from commencing.

Fessel J Alzheimers Dement (N Y). 2021; 7(1):e12199.

PMID: 34337137 PMC: 8319660. DOI: 10.1002/trc2.12199.


Mitochondrial medicine therapies: rationale, evidence, and dosing guidelines.

Barcelos I, Shadiack E, Ganetzky R, Falk M Curr Opin Pediatr. 2020; 32(6):707-718.

PMID: 33105273 PMC: 7774245. DOI: 10.1097/MOP.0000000000000954.


Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy.

Tapias V, Jainuddin S, Ahuja M, Stack C, Elipenahli C, Vignisse J Hum Mol Genet. 2018; 27(16):2874-2892.

PMID: 29860433 PMC: 6077804. DOI: 10.1093/hmg/ddy201.